Bispecific Antibodies Market By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Application (BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others), By End-User (Hospitals, Clinics and Research Centers) and By Region - Market Trends, Analysis, and Forecast till 2030.

Growing numbers of cancer patients and improvements in treatment technologies

One of the factors propelling this market is the rise in patient mortality and morbidity rates. For example, the World Health Organization estimates that there are roughly 14 million new cases of cancer each year, and the number is rising steadily. In 2021, it is anticipated that nearly 1.9 million new cases of cancer will be diagnosed.

Increasing financial support to fully realize the potential of highly successful bispecific antibody medication therapy

Bispecific antibodies are developed and produced by several pharmaceutical companies. For example, in December 2016, Abpro and MedImmune, LLC worked together to create a novel bispecific antibody called Ang2-VEGF, which targets both vascular endothelial growth factor and angiopoietin-2. It is anticipated that government funding will support ongoing research and development.